Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine alone.

NCT Number	NCT05342792
Lead Sponsor	Sun Yat-sen University Collaborators: Tongji Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Xiangya Hospital of Central South University, Affiliated Cancer Hospital of Guizhou Medical University, Cancer Hospital of Guangxi Medical University, First People's Hospital of Foshan, Chongqing University Cancer Hospital, Hubei Cancer Hospital, Hunan Cancer Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Fifth Affiliated Hospital, Sun Yat-Sen University, Shandong Provincial Hospital
Conditions	Nasopharyngeal Carcinoma
Enrollment	556 participants
Start Date	2022-04-17
Primary Completion	2027-06 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2022-04-25